[pT1G3 tumor of the bladder]

Area of Science:

• Urology
• Oncology
• Pathology

Background:

• Superficial bladder tumors are typically managed with transurethral resection (TUR) followed by chemotherapy or immunotherapy, except for carcinoma in situ (Tis).
• pT1G3 bladder tumors (BT) present significant management challenges due to high recurrence and progression rates.
• Therapeutic decisions for pT1G3 BT, especially monofocal cases, remain a subject of debate.

Purpose of the Study:

• To evaluate the outcomes of radical cystectomy versus transurethral resection (TUR) for pT1G3 bladder tumors (BT).
• To determine the optimal management strategy for pT1G3 bladder tumors (BT), particularly in the presence of carcinoma in situ (Tis).

Main Methods:

• Retrospective analysis of 109 patients with pT1G3 bladder tumors (BT) treated between 1984 and 1994.
• Comparison of outcomes between 47 patients who underwent radical cystectomy and 62 patients treated with transurethral resection (TUR).
• Emphasis on frequent random biopsies during TUR to detect foci of Tis.

Main Results:

• Radical cystectomy is mandatory when carcinoma in situ (Tis) is present in pT1G3 bladder tumors (BT).
• Transurethral resection (TUR) for pT1G3 bladder tumors (BT) necessitates frequent and accurate random biopsies to identify Tis.
• Management of monofocal pT1G3 bladder tumors (BT) continues to present therapeutic challenges.

Conclusions:

• For pT1G3 bladder tumors (BT) with Tis, radical cystectomy is the definitive treatment.
• Transurethral resection (TUR) for pT1G3 bladder tumors (BT) without Tis requires vigilant surveillance with random biopsies to detect Tis.
• Further research is needed to address the therapeutic uncertainties in managing monofocal pT1G3 bladder tumors (BT).